New data from Syncona’s Autolus holding – Syncona (SYNC), a leading healthcare company focused on founding, building and funding global leaders in life science, has this morning made note of the announcement that its portfolio company, Autolus Therapeutics (Autolus), announced new data highlighting progress on its next-generation programmed T cell therapies to treat patients with relapsed/refractory diffuse large B-cell lymphoma and pediatric acute lymphoblastic leukemia. The data were presented at the 61st American Society of Hematology annual meeting and exposition in Orlando, FL.
About AUTO3
AUTO3 is a programmed T cell therapy containing two independent chimeric antigen receptors targeting CD19 and CD22 that have each been independently optimized for single target activity. By simultaneously targeting two B cell antigens, AUTO3 is designed to minimize relapse due to single antigen loss in patients with B cell malignancies. AUTO3 is currently being tested in pediatric ALL in the AMELIA clinical trial and in diffuse large B cell lymphoma in the ALEXANDER clinical trial.
More information on Autolus and the new data released this morning can be accessed by referring to Syncona’s official announcement.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
SYNC: New data from Syncona’s Autolus holding